HyperphosphatemiaNCT00567723
Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)
An observational study of Hyperphosphatemia, run by Shire at 199 sites in United States.
Trial summary
Patients who have been treated with Fosrenol for a minimum of 12 consecutive weeks and are receiving dialysis will be followed for 5 years to compare mortality, bone fractures and incidence of selected morbidities to patients with no lanthanum exposure and to patients being treated for hyperphosphatemia with any… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hyperphosphatemia
- How many people
- 2,105 participants
- Where
- 199 sitesUnited States
- Study dates
- 25 Apr 2006to 7 Jun 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients for the Historical Control and Concomitant Therapy Groups will be selected from the United States Renal Data System (USRDS). The Test Group will consist of patients who have had a minimum of 12 consecutive weeks of exposure to Fosrenol (lanthanum carbonate).
Who may be able to join
- Signed informed consent
- Patient must have ESRD and be receiving dialysis
- Prior treatment with Fosrenol for a minimum of 12 consecutive weeks
- Primary payer of healthcare must be Medicare (patient must supply Medicare Claim Number)
- Patient must be 18 years of age or older
Who cannot join
- Patients that do not meet inclusion criteria
Trial locations and contacts
199 sites in 1 country.
199 sites in 1 country
United States199 sites
Great Lakes Renal Network
Alma, Michigan, 48801
Nephrology and Internal Medicine
Anderson, South Carolina, 29621
Fox Valley Nephrology Partners, SC
Appleton, Wisconsin, 54911
Arlington Nephrology, PA
Arlington, Texas, 76015
Mountain Kidney
Asheville, North Carolina, 28801
North Georgia Nephrology Consultant
Athens, Georgia, 30606
Southwest Atlanta Nephrology, PC
Atlanta, Georgia, 30331
North Atlantic Kidney Specialist
Atlanta, Georgia, 30342
AtlantaDavita East
Atlanta, Georgia
Davita South Fulton
Atlanta, Georgia
Kidney Care Associates, LLC
Augusta, Georgia, 30901
Fox Valley Dialysis
Aurora, Illinois, 60504
DaVita JHHS Bond Street
Baltimore, Maryland
Renal Associates of Baton Rouge
Baton Rouge, Louisiana, 70809
Clinical Research Center, Inc.
Birmingham, Alabama, 35213
Table Rock Dialysis
Boise, Idaho
Pharmaceutical Research Organization
Bountiful, Utah
PAB Clinical Resesarch
Brandon, Florida, 33511
Brenham
Brenham, Texas
Kidney Care Associates, PLLC
Brooklyn, New York, 11212
Angelo Magno, MD
Brooklyn, New York, 11228
Brookdale Physicians Dialysis associates, P.C.
Brooklyn, New York
University of Vermont, Fletcher Allen Health Care
Burlington, Vermont, 05401
Nephrology Assciates of Central PA, INC
Camp Hill, Pennsylvania, 17011
Celia Dill Dialysis Center
Carmel, New York
University of North Carolina Division of Nephrology & Hypertension
Chapel Hill, North Carolina, 27599
Charlotte Dialysis
Charlotte, North Carolina
Jefferson Nephrology Ltd
Charlottesville, Virginia, 22902
Great Bridge Dialysis Center
Chesapeake, Virginia
University of Chicago Medical Center
Chicago, Illinois, 60617
University of Cincinnati
Cincinnati, Ohio, 45206
Nephrology and Hypertension
Clinton, Maryland, 20735
Health Sciences Center
Columbia, Missouri, 65212
South Florida Nephrology Group
Coral Springs, Florida
California Kidney Specialist
Covina, California, 91723
Atlantic Avenue Medical Clinic
Cudahy, California, 90201
Geisinger Medical Center
Danville, Pennsylvania, 17822
Nephrology Consultants, PA
Daytona Beach, Florida, 32114
Purity Dialysis Centers
Delafield, Wisconsin, 53018
Associates in Nephrology
Des Plaines, Illinois, 60016
Douglas Dialysis
Douglas, Georgia
Renal Physicians of Georgia
Dublin, Georgia, 31021
Hypertension & Nephrology Associates, PA
Eatontown, New Jersey, 07724
DaVita Edison
Edison, New Jersey
Kidney Consultants fo El Paso, P.A.
El Paso, Texas
Albemarle Nephrology Associates
Elizabeth City, North Carolina, 27909
AMS Research
Elmira, New York, 14905
Renal Care of Erie
Erie, Pennsylvania, 16502
Evanston Northwestern Healthcare
Evanston, Illinois, 60201
Nephrology Associates, LLC
Evansville, Indiana, 47714
Associates in Nephrology
Evergreen Park, Illinois, 60805
Exton Dialysis Center
Exton, Pennsylvania, 19341
Nephrology Associates of Northern Virgina
Fairfax, Virginia, 22033
Horowitz and Krahn
Fall River, Massachusetts, 02720
Nephrology Associates, PC
Flushing, New York, 11355
TriMark Physicians Group
Fort Dodge, Iowa, 50501
DaVita Fort Myers
Fort Myers, Florida
DaVita Frederick Dialysis #3373
Frederick, Maryland
Nephrology Associates
Ft. Pierce, Florida, 34950
Nephrology Specialists PC
Gary, Indiana, 46408
Glen Burnie Dialysis Center
Glen Burnie, Maryland
Altru Health System Research Center
Grand Forks, North Dakota, 58201
PDI Grand Rapids East
Grand Rapids, Michigan
North Shore University Hospital
Great Neck, New York, 11021
Promod K. Duggal, MD, PC
Greenbelt, Maryland, 20770
Carolina Nephrology, PA
Greenville, South Carolina, 29605
North Suburban Nephrology, LLC
Gurnee, Illinois, 60031
Dialysis Care of Richmond County
Hamlet, North Carolina
Hartford North
Hartford, Connecticut
East Bay-South Hayward Dialysis Center
Hayward, California, 94544
Clinical Research Consultants
Hoover, Alabama
Med-Center Dialysis
Houston, Texas, 77002
Innovative Renal Care
Houston, Texas, 77003
Med-Center Dialysis
Houston, Texas, 77004
Northwest Kidney Center
Houston, Texas, 77004
Greater Houston Kidney Specialist
Houston, Texas, 77030
Kidney Associates, PLLC
Houston, Texas, 77030
Northwest Kidney Center
Houston, Texas, 77092
DaVita Northstar Dialysis
Houston, Texas
Outcomes Research International, Inc
Hudson, Florida, 34668
Internal Medicine Nephrology/Hypertension
Kingstree, South Carolina, 29556
Newman
Knoxville, Tennessee, 37921
G. Edward Newman, MD, PLLC
Knoxville, Tennessee, 37923
Gundersen Lutheran, Ltd
La Crosse, Wisconsin, 54601
Central Florida Kidney Care, PA
Lakeland, Florida, 33805
Lakewood Community Dialysis Center
Lakewood, Washington
Davita Lancaster
Lancaster, Pennsylvania
Mid Michigan Kidney Specialists
Lansing, Michigan, 48912
Lawrenceburg Dialysis Center
Lawrenceburg, Indiana, 47025
Lewistown Dialysis Center
Lewistown, Pennsylvania, 17044
Lake County
Libertyville, Illinois
Renal Research Center
Los Alamitos, California, 90720
USC Kidney Center
Los Angeles, California, 90033
Beverly Nephrology
Los Angeles, California, 90048
Tower Nephrology Medical Group
Los Angeles, California, 90048
USC DaVita Dialysis Center
Los Angeles, California
Renal Medical Associates
Lynwood, California, 90262
Renal Physicians of Georgia
Macon, Georgia, 31217
West Bank Nephrology
Marrero, Louisiana, 70072
Piedmont Medical and Renal Associates
Martinsville, Virginia, 24112
Internal Medicina and Nephrology
Maynardville, Tennessee, 37807
Memphis Central DaVita
Memphis, Tennessee
Miami Kidney Group
Miami, Florida, 33143
Nephrology Associates of South Miami
Miami, Florida, 33173
Nephrology Specialists
Michigan City, Indiana, 46360
University of South Alabama
Mobile, Alabama, 36617
Reading Nephrology, Ltd.
Mohnton, Pennsylvania, 19540
Montgomery Kidney Specialists
Montgomery, Alabama, 36106
Center for Kidney Care
Mount Laurel, New Jersey
Renal Associates of Central Indiana
Muncie, Indiana, 47303
Renal Associates of Central Indiana
Muncie, Indiana, 47304
Ball Memorial Hospital
Muncie, Indiana
Nampa DaVita Dialysis
Nampa, Idaho
VA Tennessee Valley, Health Care System
Nashville, Tennessee, 37212
Metabolism Associates
New Haven, Connecticut, 06511
LSU Healthcare Network
New Orleans, Louisiana, 70112
Westbank Chronic Renal Center
New Orleans, Louisiana
Lower Manhattan Dialysis Center
New York, New York, 10016
Bronx Dialysis center
New York, New York
Peninsula Dialysis
Newport News, Virginia, 23604
Charleston Nephrology Associates
North Charleston, South Carolina
Valley Renal Medical Group
Northridge, California, 91324
Nephrology of Northern Utah
Ogden, Utah
Olathe DaVita
Olathe, Kansas
Nephrology Associates of Central Florida
Orlando, Florida, 32804
Fox Valley Nephrology Partners, PC
Oshkosh, Wisconsin, 54904
DaVita-Johnson County Dialysis
Overland Park, Kansas
Rivertowne Davita Dialysis
Oxon Hill, Maryland, 20745
Desert Nephrolgy Medical Group
Palm Springs, California, 92262
Palo Alto Nephrology
Palo Alto, California, 94304
Nephrology Associates Research Center
Panama City, Florida, 32401
Nephrology & Hypertension Consultants, PC
Park Ridge, Illinois, 60068
Pasadena Nephrology
Pasadena, California, 91105
A Unique Kidney Center, LLC
Pembroke Pines, Florida, 33024
Renal Care Associates
Peoria, Illinois
Pennyslvania Nephrology Associates, PC
Philadelphia, Pennsylvania, 19106
Davita West Philadelphia
Philadelphia, Pennsylvania
Franklin Dialysis Center
Philadelphia, Pennsylvania
PharmResearch, Inc.
Pinecrest, Florida, 33156
Davita-Greater Portsmouth
Portsmouth, Virginia
Portsmouth Dialysis Center-DaVita
Portsmouth, Virginia
Syed Shah
Pottsville, Pennsylvania, 17901
Central Utah Clinic
Provo, Utah, 84604
Dialysis Care of Hoke County
Raeford, North Carolina
Reidsville Dialysis
Reidsville, North Carolina
Nephrology Specialists, PC
Richmond, Virginia, 23229
Nephrology Associates
Rochester, New York, 14626
University of Rochester Nephrology Unit
Rochester, New York, 14642
Biolab Research, LLC
Rockville, Maryland, 20852
Island Renal Associates, PC
Rockville Centre, New York, 11570
William Beaumont Hospital
Royal Oak, Michigan, 48073
Capital Nephrology
Sacramento, California, 95825
Syed Shah
Saint Clair, Pennsylvania, 17970
Citrus Valley Dialysis Center
San Bernardino, California
California Kidney Specialist
San Dimas, California, 91773
San Francisco Dialysis Center # 3830
San Francisco, California
Habib A. Tobbagi, MD
San Jose, California, 95112
Sauget Dialysis
Sauget, Illinois, 62206
Williams Street Dialysis
Savannah, Georgia
Selma DaVita Dialysis
Selma, California
Northwest Louisiana Nephrology, LLC
Shreveport, Louisiana, 71101
Southern Pines Dialysis
Southern Pines, South Carolina
Western New England Renal Transplant Association
Springfield, Massachusetts, 01107
Clinical Research Development Association, LLC
Springfield Gardens, New York, 11413
Douglas T. Domoto MD, JD, PC
St Louis, Missouri, 63103
Washington University School of Medicine
St Louis, Missouri, 63108
Saint Louis University Department of Internal Medicine
St Louis, Missouri, 63110
SUNY at Stony Brook NY
Stony Brook, New York, 11794
Syosset Kidney Center
Syosset, New York, 11791
Tampa Bay Nephrology Associates
Tampa, Florida, 33603
Genesis Clinical Research
Tampa, Florida, 33614
Nephrology Consultants of Northwest Ohio
Toledo, Ohio, 43606
Veritas Clinical Specialists, Ltd
Topeka, Kansas, 66606
Dennis Artzer
Topeka, Kansas
Torrington Dialysis
Torrington, Connecticut
Pear Tree Dialysis
Ukiah, California
Davita of Landover
Upper Marlboro, Maryland
High Desert Nephrology
Victorville, California, 92395
Cumberland Nephrology Associates, PA
Vineland, New Jersey, 08360
Renal Medical Group
Visalia, California, 93277
Macomb Kidney Center
Warren, Michigan
Washington Dialysis
Washington, Pennsylvania, 15301
Davita-Brentwood
Washington D.C., District of Columbia
Lee Street Dialysis
Washington D.C., District of Columbia
Union Plaza Dialysis Center
Washington D.C., District of Columbia
Waycross Dialysis Facility
Waycross, Georgia, 31501
Waycross Dialysis Facility
Waycross, Georgia
Dialyis Corporation of America
Wellsboro, Pennsylvania, 16901
Reading Nephrology, Ltd.
West Reading, Pennsylvania, 19611
Carroll County Dialysis Facility
Westminster, Maryland, 21157
Patel
Wichita Falls, Texas, 76301
Southeastern Nephrology Associates
Wilmington, North Carolina, 28401
DaVita Wilson Dialysis #3032
Wilson, North Carolina
Nephrology Associates, PLLC
Winston-Salem, North Carolina, 27103
Reading Nephrology, Ltd
Wyomissing, Pennsylvania, 19610
Yonkers Nephrology, PC
Yonkers, New York, 10710
Saint Elizabeth Healthcare Department of Research
Youngstown, Ohio, 44501
NAI fo Kidney Care
Youngstown, Ohio, 44514
North Valley Nephrology
Yuba City, California, 95991
About this study
Official title: A Phase-IV, Long-term, Observational Safety Study in End Stage Renal Disease Subjects Treated With Lanthanum Carbonate (Fosrenol)
Patients who have been treated with Fosrenol for a minimum of 12 consecutive weeks and are receiving dialysis will be followed for 5 years to compare mortality, bone fractures and incidence of selected morbidities to patients with no lanthanum exposure and to patients being treated for hyperphosphatemia with any marketed product.
- Conditions
- Hyperphosphatemia
- Medical subject headings
- Hyperphosphatemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| 1 | Test group: Patients who have received a minimum of 12 consecutive weeks of treatment with Fosrenol | |
| 2 | Historical control group: Patients with no lanthanum exposure | |
| 3 | Concomitant therapy group: Patients being treated for hyperphosphatemia with any marketed product |
What is being measured
The primary outcome is the main question the study is designed to answer.
Compare all-cause mortality and bone fractures among three groups of subjects with end stage renal disease (ESRD)
Measured: 5 years
Secondary outcomes (1)
Compare the incidence of selected morbidities among three groups of patients with ESRD
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Dec 2007 (estimated)
- Study start25 Apr 2006
- Primary completion7 Jun 2016
- Study completion7 Jun 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for HyperphosphatemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,105 participants (actual)
Sponsor and investigators
- Lead sponsor
- Shire
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Study Director, Study director, Takeda
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00567723
- Sponsor's protocol ID
- SPD405-404
- Status last verified
- Mar 2021
- First submitted
- 3 Dec 2007
- Last updated
- 17 Mar 2021
- Results posted
- No
- Data monitoring committee
- No
Publications
Hutchison A, Whelton A, Thadhani R, Achenbach H, Vergani A, Wu J, Hall G. Long-Term Mortality and Bone Safety in Patients with End-Stage Renal Disease Receiving Lanthanum Carbonate. Nephron. 2018;140(4):265-274. doi: 10.1159/000492603. Epub 2018 Oct 23.
PubMed 30352437Hutchison AJ, Wilson RJ, Garafola S, Copley JB. Lanthanum carbonate: safety data after 10 years. Nephrology (Carlton). 2016 Dec;21(12):987-994. doi: 10.1111/nep.12864.
PubMed 27479781
Study at a glance
From the registry record, last updated by the sponsor on 17 Mar 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase-IV, Long-term, Observational Safety Study in End Stage Renal Disease Subjects Treated With Lanthanum Carbonate (Fosrenol)
- ClinicalTrials.gov ID
- NCT00567723
- Acronym / sponsor ID
- SPD405-404
- Conditions
- Hyperphosphatemia
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 2,105 participants (actual)
- Lead sponsor
- ShireIndustry (pharma, biotech, devices)
- Study start
- 25 Apr 2006 (actual)
- Primary completion
- 7 Jun 2016 (actual)
- Study completion
- 7 Jun 2016 (actual)
- First posted
- 5 Dec 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients who have been treated with Fosrenol for a minimum of 12 consecutive weeks and are receiving dialysis will be followed for 5 years to compare mortality, bone fractures and incidence of selected morbidities to patients with no lanthanum exposure and to patients being treated for hyperphosphatemia with any marketed product.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 1 | – | –Test group: Patients who have received a minimum of 12 consecutive weeks of treatment with Fosrenol |
| 2 | – | –Historical control group: Patients with no lanthanum exposure |
| 3 | – | –Concomitant therapy group: Patients being treated for hyperphosphatemia with any marketed product |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients for the Historical Control and Concomitant Therapy Groups will be selected from the United States Renal Data System (USRDS). The Test Group will consist of patients who have had a minimum of 12 consecutive weeks of exposure to Fosrenol (lanthanum carbonate).
Key inclusion criteria (5 listed)
- Signed informed consent
- Patient must have ESRD and be receiving dialysis
- Prior treatment with Fosrenol for a minimum of 12 consecutive weeks
- Primary payer of healthcare must be Medicare (patient must supply Medicare Claim Number)
- Patient must be 18 years of age or older
Key exclusion criteria (1 listed)
- Patients that do not meet inclusion criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Compare all-cause mortality and bone fractures among three groups of subjects with end stage renal disease (ESRD)
Time frame: 5 years
1 secondary outcome
Compare the incidence of selected morbidities among three groups of patients with ESRD
Time frame: 5 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Mar 2021.
- Derived from this study: PubMed 30352437Hutchison A, Whelton A, Thadhani R, Achenbach H, Vergani A, Wu J, Hall G. Long-Term Mortality and Bone Safety in Patients with End-Stage Renal Disease Receiving Lanthanum Carbonate. Nephron. 2018;140(4):265-274. doi: 10.1159/000492603. Epub 2018 Oct 23.
- Derived from this study: PubMed 27479781Hutchison AJ, Wilson RJ, Garafola S, Copley JB. Lanthanum carbonate: safety data after 10 years. Nephrology (Carlton). 2016 Dec;21(12):987-994. doi: 10.1111/nep.12864.
- To obtain more information on the study, click here/on this link.Link provided by the sponsor.
Related trials for Hyperphosphatemia
Not yet recruitingObservational study
Tenapanor in Maintenance Hemodialysis Patients
Hyperphosphatemia, Maintenance Hemodialysis
Active, not recruitingPhase 3
A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
Hyperphosphatemia Patients on Hemodialysis
RecruitingObservational study
Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule
Hyperphosphatemia
Recruiting
Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
Kidney Failure, Chronic, Hyperphosphatemia
RecruitingPhase 2
Phosphate in Acute Pancreatitis
Pancreatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Study Director study director
Takeda
199 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hyperphosphatemia, run by Shire at 199 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 199 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compare all-cause mortality and bone fractures among three groups of subjects with end stage renal disease (ESRD) (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00567723, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2021.